RayKnowChina Research Map
Shortlist

NanchangNanchang University

First Affiliated Hospital of Nanchang University

南昌大学第一附属医院

Listed for 28 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at First Affiliated Hospital of Nanchang University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌6 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌8 papers led
  3. Hepatocellular carcinoma肝细胞癌63 papers led
  4. Stomach cancer胃癌98 papers led
  5. Retinoblastoma视网膜母细胞瘤0 papers led
  6. Chordoma脊索瘤1 paper led
  7. Osteosarcoma骨肉瘤24 papers led
  8. Gastrointestinal stromal tumour胃肠道间质瘤7 papers led
  9. Neuroblastoma神经母细胞瘤3 papers led
  10. Ewing sarcoma尤文肉瘤2 papers led
  11. Multiple myeloma多发性骨髓瘤3 papers led1 open trial led
  12. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病1 paper led
  13. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症5 papers led
  14. Haemophilia A血友病 A0 papers led
  15. Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征1 paper led
  16. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  17. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病4 papers led
  18. Myasthenia gravis重症肌无力4 papers led
  19. Moyamoya disease烟雾病5 papers led
  20. Takayasu arteritis大动脉炎0 papers led
  21. Idiopathic pulmonary fibrosis特发性肺纤维化4 papers led
  22. Amyotrophic lateral sclerosis肌萎缩侧索硬化症4 papers led
  23. Spinal muscular atrophy脊髓性肌萎缩症1 paper led
  24. Behçet disease白塞病0 papers led
  25. IgA nephropathyIgA 肾病2 papers led
  26. Gaucher disease戈谢病0 papers led
  27. Primary biliary cholangitis原发性胆汁性胆管炎1 paper led
  28. Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led

Not listed for: Hepatoblastoma, Aplastic anaemia, Beta thalassaemia, Fanconi anaemia, IgG4-related disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 6 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 4420242025: 002025

3 hospitals in Nanchang for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
    Phase
    Phase 1/Phase 2
    Started
    2025-11
    Registry
    NCT07258979

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Jiangmen, Kunming, Nanchang, Nanning, Shanghai, Shaoguan, Xiamen

  2. Recruiting
    Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
    Phase
    N/A
    Started
    2023-06
    Registry
    NCT05892354

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Guangxi Medical University; 13 listed hospitals as study sitesFuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Liuzhou, Nanchang, Nanning, Wuzhou

  3. Not yet recruiting
    Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT
    Phase
    Phase 3
    Started
    2021-03
    Registry
    NCT04215510

    Age 18 years to 70 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan University; 3 listed hospitals as study sitesFuzhou, Nanchang, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesInduction / concurrent chemotherapyImmunotherapyRecurrent / metastatic disease
Departments in papersMedical oncologyENT / head & neck surgery

Over half of these papers are lab or animal studies.

Papers it led6
  1. The role and molecular mechanism of NOP16 in the pathogenesis of nasopharyngeal carcinoma.2024Cell biochemistry and function
  2. Serum inflammatory markers as prognostic marker for nasopharyngeal carcinoma with liver metastasis: a multi-center retrospective study.2024European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  3. LncRNA MIR100HG Promotes Cell Proliferation in Nasopharyngeal Carcinoma by Targeting miR-136-5p/IL-6 Axis.2024Molecular biotechnology
  4. Incorporation of PD-1 blockade into induction chemotherapy improved tumor response in patients with locoregionally advanced nasopharyngeal carcinoma in a retrospective patient cohort.2024Oral oncology
  5. miRNA profiling of human nasopharyngeal carcinoma cell lines HONE1 and CNE2 after X-ray therapy.2022Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  6. Retrospective analysis of massive epistaxis and pseudoaneurysms in nasopharyngeal carcinoma after radiotherapy.2022European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
All its trials on ClinicalTrials.gov, any status7
  1. A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.RecruitingNCT07258979Study sitePhase 1/Phase 2Start 2025-11
  2. Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After ChemoradiotherapyRecruitingNCT05892354Study siteN/AStart 2023-06
  3. Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRTNot yet recruitingNCT04215510Study sitePhase 3Start 2021-03
  4. Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPCStatus unknownNCT05350891Study sitePhase 2Start 2022-05
  5. Development and Validation of a Deep Learning System for Nasopharyngeal Carcinoma Using Endoscopic ImagesStatus unknownNCT05627310Study siteStart 2022-11
  6. Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal CarcinomaStatus unknownNCT05011227Study sitePhase 2Start 2021-08
  7. Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)CompletedNCT03924986Study sitePhase 3Start 2019-03
More papers found outside PubMed (not counted)8
  1. 434 Efficacy and prognostic model development of immune checkpoint inhibitor rechallenge in recurrent or metastatic nasopharyngeal carcinoma: a real-world study2025Journal for ImmunoTherapy of Cancerconference-abstract
  2. Anti-PD-1/TGF-βRII bispecific antibody fusion protein LBL-015 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose-escalation study.2024Journal of Clinical Oncologyconference-abstract
  3. Machine-learning model of eye metastasis in nasopharyngeal carcinoma based on the AdaBoost method2023Research Squarepreprint
  4. WITHDRAWN: Targeting the PLUNC-NLRP3 inflammasome axis could inhibit nasopharyngeal carcinoma lung metastasis2023Research Squarepreprint
  5. Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma2022Figsharedataset
  6. miRNA profiling of human nasopharyngeal carcinoma cell lines HONE1 and CNE2 after X-ray therapy2022Zenodo (CERN European Organization for Nuclear Research)dataset
  7. Correlative Analysis of Massive Epistaxis and Pseudoaneurysms in Nasopharyngeal Carcinoma after Radiotherapy and a 10-Year Review2021Clinical Oncology and Researcharticle
  8. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 8 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 2220242025: 222025

3 hospitals in Nanchang for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Registry
    NCT06780111

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Hefei, Nanchang, Xiamen, Xuzhou, Zhengzhou

  2. Recruiting
    Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
    Phase
    Phase 3
    Started
    2019-09
    Registry
    NCT04135664

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest Hospital; 5 listed hospitals as study sitesNanchang, Shanghai, Tianjin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesMolecular markers & genomicsImaging & AIEarly detection & endoscopy
Departments in papersGastroenterology / hepatologyMedical oncologySurgery (general/hepatobiliary/pancreatic)

Over half of these papers are lab or animal studies.

Papers it led8
  1. Macrophage efferocytosis mediated by the TP63-RAC2 pathway promotes immunosuppressive remodeling in esophageal cancer.2026Cell reports. MedicineFree full text
  2. TRAF7 inhibits proliferation and migration of esophageal squamous cell carcinoma by ubiquitination-mediated degradation of SOX12.2025Biochemistry and cell biology = Biochimie et biologie cellulaire
  3. Entirely Intramural Growth Pattern: A Rare Presentation of Esophageal Squamous Cell Carcinoma and Review of the Literature.2025Zeitschrift fur Gastroenterologie
  4. A novel disulfidptosis-related LncRNA prognostic risk model: predicts the prognosis, tumor microenvironment and drug sensitivity in esophageal squamous cell carcinoma.2024BMC gastroenterologyFree full text
  5. Clinical features and treatment outcomes of PD-1 inhibitor therapy in elderly patients (≥ 65 years) with advanced esophageal squamous cell carcinoma: a real-world study.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  6. Long non-coding RNA NCK1-AS1 functions as a ceRNA to regulate cell viability and invasion in esophageal squamous cell carcinoma via microRNA-133b/ENPEP axis.2023Cell cycle (Georgetown, Tex.)Free full text
  7. The Correlation of Mouse Double Minute 4 (MDM4) Polymorphisms (rs4245739, rs1563828, rs11801299, rs10900598, and rs1380576) with Cancer Susceptibility: A Meta-Analysis.2022Medical science monitor : international medical journal of experimental and clinical researchFree full text
  8. Silencing of UAP1L1 inhibits proliferation and induces apoptosis in esophageal squamous cell carcinoma.2021Molecular carcinogenesis
All its trials on ClinicalTrials.gov, any status8
  1. Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)RecruitingNCT06780111Study sitePhase 1/Phase 2Start 2025-07
  2. Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell CarcinomaRecruitingNCT04135664Study sitePhase 3Start 2019-09
  3. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell CarcinomaTerminatedNCT05461794Study sitePhase 2Start 2022-10
  4. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.CompletedNCT05142709Study siteStart 2021-10
  5. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
  6. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04848753Study sitePhase 3Start 2021-05
  7. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
  8. Robot-assisted Esophagectomy Versus Conventional Thoracoscopic EsophagectomyStatus unknownNCT03094351Study sitePhase 3Start 2017-07
More papers found outside PubMed (not counted)4
  1. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figsharedataset
  2. A phase II study of neoadjuvant immunotherapy combined with chemotherapy (camrelizumab plus albumin paclitaxel and carboplatin) in resectable thoracic esophageal squamous cell cancer (NICE study): Interim results.2021Journal of Clinical Oncologyconference-abstract
  3. LRP16 Promotes Proliferation and Migration of Esophageal Squamous Cell Carcinoma by Regulating Hippo Signaling Pathway2021Research Squarepreprint
  4. Robot-assisted Versus Conventional Minimally Invasive Esophagectomy for Resectable Esophageal Squamous Cell Carcinoma2021Annals of Surgeryarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 63 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
63
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 111120212022: 121220222023: 131320232024: 141420242025: 10102025

3 hospitals in Nanchang for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06954467

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Harbin, Hefei, Nanchang, Shanghai, Shenyang, Zhengzhou

  2. Recruiting
    Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
    Phase
    Not given
    Started
    2022-09
    Registry
    NCT06822413

    Age not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 3 listed hospitals as study sitesHangzhou, Nanchang, Shanghai

  3. Not yet recruiting
    A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data
    Phase
    Not given
    Started
    2025-10
    Registry
    NCT07156617

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesHaikou, Nanchang, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionHepatitis B & cirrhosis
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyMedical oncologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led63
  1. hnRNPA3 promotes the proliferation of hepatocellular carcinoma cells by stabilizing GLI2 proteins and activating Hedgehog pathway.2026Hepatology international
  2. FBXO22 promotes hepatocellular carcinoma progression via paracrine myo‑inositol‑induced M2‑type polarization of macrophages.2026International journal of molecular medicineFree full text
  3. c‑Myc‑regulated RPLP0 via the ROS‑mediated JAK2/STAT3 positive feedback loop facilitates hepatocellular carcinoma malignancy progression.2026International journal of oncologyFree full text
  4. The safety and efficacy of tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors combined with HAIC/TACE in the treatment of recurrent unresectable hepatocellular carcinoma.2025BMC cancerFree full text
  5. TRIM47-facilitated PLK1 stabilization promotes the proliferation of liver cancer cells.2025Cellular oncology (Dordrecht, Netherlands)Free full text
  6. Research Trends on Nanomaterials and Hepatocellular Carcinoma From 1999 to 2024: A Bibliometric Analysis.2025Drug design, development and therapyFree full text
  7. Elevated platelet distribution width and diabetes may serve as preoperative predictors of microvascular invasion in primary hepatocellular carcinoma.2025Journal of cancer research and clinical oncologyFree full text
  8. Transarterial Embolization Using an Inorganic Phosphate Binder Modulates Immunity- and Angiogenesis-Related Factors in a Rat Model of Liver Cancer.2025Journal of vascular and interventional radiology : JVIR
  9. Whole transcriptome and proteome analyses identify ncRNAs and mRNAs to predict competing endogenous RNA networks in hepatitis B virus-induced hepatocellular carcinoma.2025Microbial pathogenesis
  10. Comprehensive Analysis of circRNA, lncRNA, miRNA and mRNA Expression Profiles and Their Competing Endogenous RNA Networks in Hepatitis B Virus-Related Hepatocellular Carcinoma.2025Molecular biotechnology
  11. Pan-cancer analysis of oncogenic role of MAGOH and experiment validation in hepatocellular carcinoma.2025Scientific reportsFree full text
  12. Integrating single-cell RNA-Seq and bulk RNA-Seq data to explore the key role of fatty acid metabolism in hepatocellular carcinoma.2025Scientific reportsFree full text
  13. The impact of metabolic syndrome on hepatocellular carcinoma: a mendelian randomization study.2025Scientific reportsFree full text
  14. HIV/HBV coinfection: understanding the complex interactions and their impact on spontaneous HBV clearance, chronic liver damage, cirrhosis, and hepatocellular carcinoma.2024AIDS reviews
  15. miR-557 inhibits hepatocellular carcinoma progression through Wnt/β-catenin signaling pathway by targeting RAB10.2024AgingFree full text
  16. Beneficial effects of maintaining liver function during hepatic arterial infusion chemotherapy combined with tyrosine kinase and programmed cell death protein-1 inhibitors on the outcomes of patients with unresectable hepatocellular carcino2024BMC cancerFree full text
  17. A hsa_circ_001726 axis regulated by E2F6 contributes to metastasis of hepatocellular carcinoma.2024BMC cancerFree full text
  18. Epigenetic silencing of LDHB promotes hepatocellular carcinoma by remodeling the tumor microenvironment.2024Cancer immunology, immunotherapy : CIIFree full text
  19. Development and Validation of a Carbohydrate Metabolism-Related Model for Predicting Prognosis and Immune Landscape in Hepatocellular Carcinoma Patients.2024Current medical science
  20. Cardiovascular toxicities following the use of tyrosine kinase inhibitors in hepatocellular cancer patients: a retrospective, pharmacovigilance study.2024Expert opinion on drug safety
  21. Innovative Dual mRNA-Lipid Nanoparticle Therapy Targeting CRHBP and CFHR3 for Enhanced Treatment of Hepatocellular Carcinoma.2024International journal of nanomedicineFree full text
  22. Exosomal lncRNA HEIH, an essential communicator for hepatocellular carcinoma cells and macrophage M2 polarization through the miR-98-5p/STAT3 axis.2024Journal of biochemical and molecular toxicology
  23. Development and validation of nomograms to evaluate the survival outcome of HCC patients undergoing selective postoperative adjuvant TACE.2024La Radiologia medicaRCT
  24. MRI-based clinical-radiomics nomogram model for predicting microvascular invasion in hepatocellular carcinoma.2024Medical physics
  25. AURKB targets DHX9 to promote hepatocellular carcinoma progression via PI3K/AKT/mTOR pathway.2024Molecular carcinogenesis
  26. Upregulation of CYR61 by TGF-β and YAP signaling exerts a counter-suppression of hepatocellular carcinoma.2024The Journal of biological chemistryFree full text
  27. Establishment of a hydrodynamic delivery system in ducks.2024Transgenic research
  28. CENPB promotes the proliferation of hepatocellular carcinoma and is directly regulated by miR-29a.2023AgingFree full text
  29. PCNT is a prognostic biomarker correlated with tumor immune microenvironment in hepatocellular carcinoma and promotes tumor progression by inhibiting cell cycle arrest.2023AgingFree full text
  30. Pan-cancer analysis reveals potential of FAM110A as a prognostic and immunological biomarker in human cancer.2023Frontiers in immunologyFree full text
  31. Hepatic artery intervention combined with immune-targeted therapy is superior to sequential therapy in BCLC-C hepatocellular carcinoma.2023Journal of cancer research and clinical oncologyFree full text
  32. Rare benign liver tumors that require differentiation from hepatocellular carcinoma: focus on diagnosis and treatment.2023Journal of cancer research and clinical oncologyFree full text
  33. Differential diagnosis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma based on spatial and channel attention mechanisms.2023Journal of cancer research and clinical oncologyFree full text
  34. Development and Validation of a Nomogram for Predicting Postoperative Early Relapse and Survival in Hepatocellular Carcinoma.2023Journal of the National Comprehensive Cancer Network : JNCCNRCT
  35. Arginine methylation of HSPA8 by PRMT9 inhibits ferroptosis to accelerate hepatitis B virus-associated hepatocellular carcinoma progression.2023Journal of translational medicineFree full text
  36. Important oncogenic and immunogenic roles of SPP1 and CSF1 in hepatocellular carcinoma.2023Medical oncology (Northwood, London, England)Free full text
  37. The relationship between VEGF-460(T>C) polymorphism and cancer risk: A systematic review and meta-analysis based on 46 reports.2023MedicineFree full text
  38. Overcoming the resistance of hepatocellular carcinoma to PD-1/PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles.2023OncoimmunologyFree full text
  39. Ferritin Nanocaged Doxorubicin Potentiates Chemo-Immunotherapy against Hepatocellular Carcinoma via Immunogenic Cell Death.2023Small methods
  40. Postoperative adjuvant transarterial chemoembolisation improves survival of hepatocellular carcinoma patients with microvascular invasion: A multicenter retrospective cohort.2023United European gastroenterology journalFree full text
  41. The combination of serum oligosaccharide chain (G-test), alpha-fetoprotein, and aspartate aminotransferase to alanine aminotransferase ratio provides the optimal diagnostic value for early detection of hepatocellular carcinoma.2022BMC cancerFree full text
  42. A new finding in the key prognosis-related proto-oncogene FYN in hepatocellular carcinoma based on the WGCNA hub-gene screening trategy.2022BMC cancerFree full text
  43. Correlation of LAGE3 with unfavorable prognosis and promoting tumor development in HCC via PI3K/AKT/mTOR and Ras/RAF/MAPK pathways.2022BMC cancerFree full text
  44. No significant relationship exists between tumor size and prognosis in distant metastatic hepatocellular carcinoma: a propensity score matching analysis based on SEER database.2022BMC gastroenterologyFree full text
  45. Prognostic signature for hepatocellular carcinoma based on 4 pyroptosis-related genes.2022BMC medical genomicsFree full text
  46. New indexes derived from routine blood tests and their clinical application in hepatocellular carcinoma.2022Clinics and research in hepatology and gastroenterology
  47. PCSK9 Suppresses M2-Like Tumor-Associated Macrophage Polarization by Regulating the Secretion of OX40L from Hepatocellular Carcinoma Cells.2022Immunological investigations
  48. Combined identification of three lncRNAs in serum as effective diagnostic and prognostic biomarkers for hepatitis B virus-related hepatocellular carcinoma.2022International journal of cancer
  49. NOL12 as an Oncogenic Biomarker Promotes Hepatocellular Carcinoma Growth and Metastasis.2022Oxidative medicine and cellular longevityFree full text
  50. A novel four-gene signature for predicting the prognosis of hepatocellular carcinoma.2022Scandinavian journal of gastroenterology
  51. A bile acid-related prognostic signature in hepatocellular carcinoma.2022Scientific reportsFree full text
  52. Association of alpha-fetoprotein and metastasis for small hepatocellular carcinoma: A propensity-matched analysis.2022Scientific reportsFree full text
  53. CircRNA circBACH1 (hsa_circ_0061395) serves as a miR-656-3p sponge to facilitate hepatocellular carcinoma progression through increasing SERBP1 expression.2021Biochemical and biophysical research communications
  54. DNAJC5 promotes hepatocellular carcinoma cells proliferation though regulating SKP2 mediated p27 degradation.2021Biochimica et biophysica acta. Molecular cell research
  55. Upregulated lncRNA DLX6-AS1 underpins hepatocellular carcinoma progression via the miR-513c/Cul4A/ANXA10 axis.2021Cancer gene therapy
  56. OATP1B1 Plays an Important Role in the Transport and Treatment Efficacy of Sorafenib in Hepatocellular Carcinoma.2021Disease markersFree full text
  57. Serum lactate level predicts 6-months mortality in patients with hepatitis B virus-related decompensated cirrhosis: a retrospective study.2021Epidemiology and infectionFree full text
  58. N6 -methyladenosine modification of circular RNA circ-ARL3 facilitates Hepatitis B virus-associated hepatocellular carcinoma via sponging miR-1305.2021IUBMB life
  59. Xeroderma Pigmentosum group D suppresses proliferation and promotes apoptosis of HepG2 cells by downregulating ERG expression via the PPARγ pathway.2021International journal of experimental pathology
  60. PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis.2021International journal of medical sciencesFree full text
  61. P53 suppresses the progression of hepatocellular carcinoma via miR-15a by decreasing OGT expression and EZH2 stabilization.2021Journal of cellular and molecular medicineFree full text
  62. AFP-L3 for the diagnosis of early hepatocellular carcinoma: A meta-analysis.2021MedicineFree full text
  63. Astragalus polysacharin inhibits hepatocellular carcinoma-like phenotypes in a murine HCC model through repression of M2 polarization of tumour-associated macrophages.2021Pharmaceutical biologyFree full text
All its trials on ClinicalTrials.gov, any status9
  1. A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world DataNot yet recruitingNCT07156617Study siteStart 2025-10
  2. JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular CarcinomaRecruitingNCT06954467Study sitePhase 2Start 2025-05
  3. Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early DiagnosisRecruitingNCT06822413Study siteStart 2022-09
  4. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  5. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Study sitePhase 3Start 2020-10
  6. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Study sitePhase 3Start 2019-06
  7. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  8. Study of BGB-A317 in Participants With Previously Treated Unresectable HCCCompletedNCT03419897Study sitePhase 2Start 2018-04
  9. A Study to Evaluate SHR-1210 in Subjects With Advanced HCCCompletedNCT02989922Study sitePhase 2Start 2016-11

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 98 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 1.0%.

Papers led
98
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
8
led by another institution
Papers led per year
2021: 171720212022: 171720222023: 141420232024: 171720242025: 28282025

3 hospitals in Nanchang for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 8

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 64 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  2. Recruiting
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    Phase
    Phase 3
    Started
    2026-12
    Registry
    NCT07789184

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an

  3. Recruiting
    Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Registry
    NCT06469944

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Fuzhou, Hangzhou, Nanchang, Shanghai, Urumqi, Xiamen, Zhengzhou

  4. Recruiting
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06532006

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xining, Xuzhou, Yinchuan, Zhengzhou

  5. Recruiting
    Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2023-04
    Registry
    NCT05918094

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 7 listed hospitals as study sitesChengdu, Dalian, Guangzhou, Harbin, Nanchang, Shanghai, Wuhan, Zhengzhou

  6. Recruiting
    The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
    Phase
    N/A
    Started
    2023-12
    Registry
    NCT06081647

    Age 18 years to 60 years (registered criteria)

    Led by Renji Hospital; 7 listed hospitals as study sitesHangzhou, Jinan, Nanchang, Nanjing, Shanghai

  7. Recruiting
    A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
    Phase
    Phase 1
    Started
    2022-02
    Registry
    NCT05262491

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Jinan, Nanchang, Tianjin

  8. Recruiting
    Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
    Phase
    Not given
    Started
    2022-09
    Registry
    NCT06822413

    Age not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 3 listed hospitals as study sitesHangzhou, Nanchang, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEarly detection & endoscopyImaging & AIPeritoneal spread & advanced disease
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)Medical oncologyENT / head & neck surgery

Over half of these papers are lab or animal studies.

Papers it led98
  1. Macrophage-derived FN1 promotes peritoneal cavity metastasis of gastric cancer by inhibiting the Hippo signaling pathway via SDC4.2026Biochimica et biophysica acta. Molecular cell research
  2. Silencing of MAT2A inhibits gastric cancer cell proliferation, migration, and invasion through activation of the p53 pathway.2026Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  3. Targeting ferroptosis in Helicobacter pylori‑associated gastric cancer development: From molecular mechanisms to application prospects (Review).2026International journal of oncologyFree full text
  4. Lipidomics and single-cell transcriptomics uncover aberrant lipid metabolism in metaplasia lesions during gastric carcinogenesis.2026Journal of gastroenterology
  5. Single-Cell and Spatial Transcriptomic Analysis Reveals Shared and Cancer-Type-Specific Cellular Interactions and Chemokine Signaling Associated With Tertiary Lymphoid Structures in Colorectal and Gastric Cancers.2026Molecular carcinogenesis
  6. Stratified and propensity score matching analysis of the effectiveness of fibrin glue in preventing postoperative bleeding after endoscopic submucosal dissection.2025Annals of medicineFree full text
  7. Clinical significance of the S204 phosphorylation of the Smad3 protein in combination with Ki67 for the metastasis and prognosis of gastric cancer.2025BMC gastroenterologyFree full text
  8. Integrated bulk and single-cell RNA profiling implicates MFAP5+ CAFs in potential role in peritoneal metastasis of gastric cancer.2025Biochemical and biophysical research communications
  9. Sex-specific effects of gastrointestinal microbiome disruptions on Helicobacter pylori-induced gastric carcinogenesis in INS-GAS mice.2025Biology of sex differencesFree full text
  10. VASN drives gastric tumorigenesis via activation of the COL4A1/PI3K/AKT axis during Helicobacter pylori infection.2025British journal of cancerFree full text
  11. Identification of HCAR1 as a ferroptosis-related biomarker of gastric cancer based on a novel ferroptosis-related prognostic model and in vitro experiments.2025Carcinogenesis
  12. Ubiquitin-specific peptidase 49 promotes adenocarcinoma of the esophagogastric junction malignant progression via activating SHCBP1-β-catenin-GPX4 axis.2025Carcinogenesis
  13. Oroxin A Induces Autophagic Cell Death in Gastric Cancer Cells Through the MAPK/ERK/REDD1 Axis.2025Cell biology international
  14. UCHL3 depletion inhibits gastric cancer progression and enhances palbociclib sensitivity by regulating the AKT/CCND1 signaling axis via ENO1 ubiquitination.2025Cell death & diseaseFree full text
  15. UBE4B promotes gastric cancer proliferation and metastasis by mediating FAT4 ubiquitination and degradation.2025Cell death & diseaseFree full text
  16. TMEM160 inhibits KEAP1 to suppress ferroptosis and induce chemoresistance in gastric cancer.2025Cell death & diseaseFree full text
  17. LITAF-NOTCH2-Bmi-1 Axis Mediates AMPK-Dependent Inhibition of Gastric Cancer Invasion and Metastasis.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  18. The association between family health and frailty in preoperative patients with gastric cancers: the mediating role of health literacy and physical activity.2025Frontiers in public healthFree full text
  19. Helicobacter pylori infection induces DNA double-strand breaks through the ACVR1/IRF3/POLD1 signaling axis to drive gastric tumorigenesis.2025Gut microbesFree full text
  20. Comprehensive evaluation of the PCDHB family in gastric cancer: Prognostic significance, immune infiltration, and experimental validation of PCDHB5's oncogenic role.2025International immunopharmacology
  21. Single-cell transcriptomic profiling uncovers cellular complexity and microenvironment in gastric tumorigenesis associated with Helicobacter pylori.2025Journal of advanced researchFree full text
  22. PDLIM4 drives gastric cancer malignant progression and cisplatin resistance by inhibiting HSP70 ubiquitination and degradation via competitive interaction with STUB1.2025Journal of nanobiotechnologyFree full text
  23. Helicobacter pylori activates DOPEY1 to promote p53 degradation through the USP7/TRIP12 axis in gastric tumorigenesis.2025Oncogene
  24. SNX5 facilitates the progression of gastric cancer by increasing the membrane localization of LRP5.2025Oncogene
  25. PRSS23-eIF4E-c-Myc axis promotes gastric tumorigenesis and progression.2025Oncogene
  26. Integrated analysis of single-cell and bulk RNA-seq reveals MAGEA3/6-associated immune subtypes and key immune genes in gastric cancer.2025PloS oneFree full text
  27. OLR1 is closely related to poor prognosis and immune cell infiltration in gastric cancer.2025Scientific reportsFree full text
  28. Construction and validation of a nomogram based on the log odds of positive lymph nodes to predict the prognosis of T1 gastric cancer.2025Scientific reportsFree full text
  29. Feasibility and safety of endoscopic full-thickness resection of large gastric subepithelial lesions outside the operating room: 10 years of experience in a large tertiary hospital in China.2025Surgical endoscopy
  30. Development of a predictive model for surgical difficulty assessment in distal gastrectomy of advanced gastric carcinoma using LASSO-random forest integrated algorithm.2025Surgical endoscopy
  31. Development and validation of a model for predicting electrocoagulation syndrome after endoscopic full-thickness resection of gastric tumors.2025Surgical endoscopy
  32. A multicenter retrospective study of PD-1 blockade plus chemotherapy as first-line therapy in advanced hepatoid adenocarcinoma of the stomach.2025The oncologistFree full text
  33. Short- and long-term outcomes of totally robotic versus robotic-assisted total gastrectomy for advanced gastric cancer: a single-center retrospective study.2025World journal of surgical oncologyFree full text
  34. Comprehensive analysis of the function of helicobacter-associated ferroptosis gene YWHAE in gastric cancer through multi-omics integration, molecular docking, and machine learning.2024Apoptosis : an international journal on programmed cell death
  35. ILF2 protein is a promising serum biomarker for early detection of gastric cancer.2024BMC cancerFree full text
  36. Bilibili, TikTok, and YouTube as sources of information on gastric cancer: assessment and analysis of the content and quality.2024BMC public healthFree full text
  37. Body image and quality of life undergoing totally robotic versus robotic-assisted distal gastrectomy: a retrospective propensity score matched cohort study.2024BMC surgeryFree full text
  38. CLEC11A expression as a prognostic biomarker in correlation to immune cells of gastric cancer.2024Biomolecules & biomedicineFree full text
  39. Screening of gastric cancer diagnostic biomarkers in the homologous recombination signaling pathway and assessment of their clinical and radiomic correlations.2024Cancer medicineFree full text
  40. YAP1-CPNE3 positive feedback pathway promotes gastric cancer cell progression.2024Cellular and molecular life sciences : CMLSFree full text
  41. Differential Expression of KIF18B in Gastric Cancer and Its Role in Chemotherapy Sensitivity.2024Critical reviews in eukaryotic gene expression
  42. Development of a urine-based metabolomics approach for multi-cancer screening and tumor origin prediction.2024Frontiers in immunologyFree full text
  43. Spatial Variation of the Gastrointestinal Microbiota in Response to Long-Term Administration of Vonoprazan in Mice With High Risk of Gastric Cancer.2024Helicobacter
  44. COMMD10 inhibited DNA damage to promote the progression of gastric cancer.2024Journal of cancer research and clinical oncologyFree full text
  45. ROS-mediated up-regulation of SAE1 by Helicobacter pylori promotes human gastric tumor genesis and progression.2024Journal of translational medicineFree full text
  46. Genome-wide DNA methylation profiling reveals a novel hypermethylated biomarker PRKCB in gastric cancer.2024Scientific reportsFree full text
  47. Comparative assessment of the capability of machine learning-based radiomic models for predicting omental metastasis in locally advanced gastric cancer.2024Scientific reportsFree full text
  48. Development and validation of a preoperative risk nomogram prediction model for gastric gastrointestinal stromal tumors.2024Surgical endoscopy
  49. Prediction Model of Ocular Metastases in Gastric Adenocarcinoma: Machine Learning-Based Development and Interpretation Study.2024Technology in cancer research & treatmentFree full text
  50. Short-term outcomes of totally robotic versus robotic-assisted distal gastrectomy for gastric cancer: a single-center retrospective study.2024World journal of surgical oncologyFree full text
  51. Hub gene identification and molecular subtype construction for Helicobacter pylori in gastric cancer via machine learning methods and NMF algorithm.2023AgingFree full text
  52. Overexpression of SATB1 correlates with epithelial-mesenchymal transition and lymphatic metastasis in gastric cancer.2023Annals of diagnostic pathology
  53. Investigation of the prevalence and risk factors of Helicobacter pylori infection and the value of different gastric cancer screening methods in a low-risk region of gastric cancer in China.2023Annals of medicineFree full text
  54. GRB7 plays a promoting role in the progression of gastric cancer.2023BMC cancerFree full text
  55. Integrated single-cell and bulk RNA sequencing analysis identifies a cancer-associated fibroblast-related gene signature for predicting survival and therapy in gastric cancer.2023BMC cancerFree full text
  56. WWP2 drives the progression of gastric cancer by facilitating the ubiquitination and degradation of LATS1 protein.2023Cell communication and signaling : CCSFree full text
  57. Clinicopathological characteristics, survival outcome and prognostic factors of very young gastric cancer.2023Clinical and experimental medicine
  58. YAP and β-catenin cooperate to drive H. pylori-induced gastric tumorigenesis.2023Gut microbesFree full text
  59. Research trends on nanomaterials in gastric cancer: a bibliometric analysis from 2004 to 2023.2023Journal of nanobiotechnologyFree full text
  60. Development and validation of a CT radiomics and clinical feature model to predict omental metastases for locally advanced gastric cancer.2023Scientific reportsFree full text
  61. Application of machine learning algorithm in predicting distant metastasis of T1 gastric cancer.2023Scientific reportsFree full text
  62. Comparable long-term survival outcomes of endoscopic therapy versus surgical therapy for T1-2N0M0 duodenal neuroendocrine tumors.2023Surgical endoscopy
  63. Role of POU1F1 promoting the properties of stemness of gastric carcinoma through ENO1-mediated glycolysis reprogramming.2023The Kaohsiung journal of medical sciencesFree full text
  64. Research trends on artificial intelligence and endoscopy in digestive diseases: A bibliometric analysis from 1990 to 2022.2023World journal of gastroenterologyFree full text
  65. Establishing a cancer driver gene signature-based risk model for predicting the prognoses of gastric cancer patients.2022AgingFree full text
  66. Potential Factors Predicting Histopathologically Upgrade Discrepancies between Endoscopic Forceps Biopsy of the Colorectal Low-Grade Intraepithelial Neoplasia and Endoscopic Resection Specimens.2022BioMed research internationalFree full text
  67. Circular RNA hsa_circ_0001658 regulates apoptosis and autophagy in gastric cancer through microRNA-182/Ras-related protein Rab-10 signaling axis.2022BioengineeredFree full text
  68. A DCS-related lncRNA signature predicts the prognosis and chemotherapeutic response of patients with gastric cancer.2022Bioscience reportsFree full text
  69. PSMA1 mediates tumor progression and poor prognosis of gastric carcinoma by deubiquitinating and stabilizing TAZ.2022Cell death & diseaseFree full text
  70. Resveratrol inhibits TGF-β1-induced EMT in gastric cancer cells through Hippo-YAP signaling pathway.2022Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  71. Identification and Validation of Immune Cells and Hub Genes in Gastric Cancer Microenvironment.2022Disease markersFree full text
  72. The management of Helicobacter pylori infection and prevention and control of gastric cancer in China.2022Frontiers in cellular and infection microbiologyFree full text
  73. An Overview of Autophagy in Helicobacter pylori Infection and Related Gastric Cancer.2022Frontiers in cellular and infection microbiologyFree full text
  74. The Hypoxic Landscape Stratifies Gastric Cancer Into 3 Subtypes With Distinct M6a Methylation and Tumor Microenvironment Infiltration Characteristics.2022Frontiers in immunologyFree full text
  75. Convergent dysbiosis of gastric mucosa and fluid microbiome during stomach carcinogenesis.2022Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  76. Probiotics mitigate Helicobacter pylori-induced gastric inflammation and premalignant lesions in INS-GAS mice with the modulation of gastrointestinal microbiota.2022Helicobacter
  77. An updated systematic review of the association between the TLR4 polymorphism rs4986790 and cancers risk.2022MedicineFree full text
  78. USP49 mediates tumor progression and poor prognosis through a YAP1-dependent feedback loop in gastric cancer.2022Oncogene
  79. ITGA5 Promotes Tumor Progression through the Activation of the FAK/AKT Signaling Pathway in Human Gastric Cancer.2022Oxidative medicine and cellular longevityFree full text
  80. Surgical and oncological outcomes of robotic- versus laparoscopic-assisted distal gastrectomy with D2 lymphadenectomy for advanced gastric cancer: a propensity score‑matched analysis of 1164 patients.2022World journal of surgical oncologyFree full text
  81. Meningeal carcinomatosis following a curative endoscopic submucosal dissection of early gastric cancer: a case report.2022Zeitschrift fur Gastroenterologie
  82. A stable gene set for prediction of prognosis and efficacy of chemotherapy in gastric cancer.2021BMC cancerFree full text
  83. Antibiotics for fever in patients without perforation after gastric endoscopic submucosal dissection and endoscopic submucosal excavation may be unnecessary: a propensity score-matching analysis.2021BMC gastroenterologyFree full text
  84. Weighted correlation network analysis identifies FN1, COL1A1 and SERPINE1 associated with the progression and prognosis of gastric cancer.2021Cancer biomarkers : section A of Disease markersFree full text
  85. LCP1 is a prognostic biomarker correlated with immune infiltrates in gastric cancer.2021Cancer biomarkers : section A of Disease markersFree full text
  86. Interactions between gastric microbiota and metabolites in gastric cancer.2021Cell death & diseaseFree full text
  87. HMGA1B/2 transcriptionally activated-POU1F1 facilitates gastric carcinoma metastasis via CXCL12/CXCR4 axis-mediated macrophage polarization.2021Cell death & diseaseFree full text
  88. Discovery and Validation of Novel Methylation Markers in Helicobacter pylori-Associated Gastric Cancer.2021Disease markersFree full text
  89. Comment on: "Long‑term persistence of gastric dysbiosis after eradication of Helicobacter pylori in patients who underwent endoscopic submucosal dissection for early gastric cancer. Gastric Cancer, 2020 Nov 17" by Watanabe et al.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  90. Upregulation of oncogene Activin A receptor type I by Helicobacter pylori infection promotes gastric intestinal metaplasia via regulating CDX2.2021Helicobacter
  91. Effect of Helicobacter pylori eradication on hyperplastic gastric polyps: A systematic review and meta-analysis.2021Helicobacter
  92. Activation of Aquaporin 5 by carcinogenic Helicobacter pylori infection promotes epithelial-mesenchymal transition via the MEK/ERK pathway.2021Helicobacter
  93. MiR-216b inhibits gastric cancer proliferation and migration by targeting PARK7.2021Indian journal of pathology & microbiology
  94. The E3 ligase HUWE1 mediates TGFBR2 ubiquitination and promotes gastric cancer cell proliferation, migration, and invasion.2021Investigational new drugs
  95. Molecular targeted treatment and drug delivery system for gastric cancer.2021Journal of cancer research and clinical oncologyFree full text
  96. High expression of NEK2 promotes gastric cancer progression via activating AKT signaling.2021Journal of physiology and biochemistry
  97. Expression and prognostic significance of the DNA damage response pathway and autophagy markers in gastric cancer.2021Neoplasma
  98. Ubiquitin-specific protease 15 contributes to gastric cancer progression by regulating the Wnt/β-catenin signaling pathway.2021World journal of gastroenterologyFree full text
Chinese-language papers (not in the count)2
  1. [Effect of jejunal feeding tube placement on complications after laparoscopic radical surgery in patients with incomplete pyloric obstruction by gastric antrum cancer].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Safety and efficacy of proximal gastrectomy with double tract anastomosis reconstruction for upper gastric cancer: a meta-ananlysis].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status26
  1. A Multifactor Prediction Model for Non-curative Outcomes in Mixed-type Early Gastric CancerCompletedNCT07096947Lead sponsorStart 2017-01
  2. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion TherapyRecruitingNCT07789184Study sitePhase 3Start 2026-12
  3. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  4. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  5. Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)RecruitingNCT06469944Study sitePhase 1/Phase 2Start 2024-09
  6. The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy ProcedureRecruitingNCT06081647Study siteN/AStart 2023-12
  7. Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT05918094Study sitePhase 3Start 2023-04
  8. A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid TumorRecruitingNCT05262491Study sitePhase 1Start 2022-02
  9. Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early DiagnosisRecruitingNCT06822413Study siteStart 2022-09
  10. Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid TumorsStatus unknownNCT06010862Study sitePhase 1Start 2023-09
  11. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  12. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  13. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  14. Efficacy and Safety of Remimazolam Tosylate for Sedation in GastroscopyStatus unknownNCT04727034Study siteN/AStart 2021-03
  15. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  16. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  17. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer DiagnosisStatus unknownNCT04440605Study siteStart 2020-07
  18. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  19. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  20. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)CompletedNCT03675737Study sitePhase 3Start 2018-11
  21. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China ExtensionWithdrawnNCT04859582Study sitePhase 3Start 2018-11
  22. Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric CancerStatus unknownNCT03273920Study siteN/AStart 2017-09
  23. Incidence of Pancreatic Fistula After Radical GastrectomyStatus unknownNCT03391687Study siteStart 2017-12
  24. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)Status unknownNCT02461407Study sitePhase 2/Phase 3Start 2015-06
  25. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric CancerCompletedNCT01774786Study sitePhase 3Start 2013-06
  26. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led no English-language PubMed papers on retinoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

8 hospitals in Nanchang for retinoblastoma176 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Erlotinib has tumor inhibitory effect in human retinoblastoma cells.2017Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Nanchang for chordoma84 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgery

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 24 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 1.1%.

Papers led
24
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 2220222023: 4420232024: 6620242025: 882025

7 hospitals in Nanchang for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Over half of these papers are lab or animal studies.

Papers it led24
  1. LncSNHGs: new targets in osteosarcoma.2025Cancer gene therapy
  2. Tanshinone II A Facilitates Chemosensitivity of Osteosarcoma Cells to Cisplatin via Activation of p38 MAPK Pathway.2025Chinese journal of integrative medicine
  3. Targeted Inhibition of NOTCH2 and Importin-β Promotes Osteogenic Differentiation of Osteosarcoma Cells.2025Drug development research
  4. Integrative bioinformatics and experimental validation identify pyrroline-5-carboxylate reductase 1 as a mitochondrial regulator and diagnostic biomarker in osteosarcoma.2025International journal of biological macromolecules
  5. TRIM47 Facilitates Osteosarcoma Progression via Destabilising FBP1 and Thus Activation of Wnt/β-Catenin Pathway.2025Journal of cellular and molecular medicine
  6. GPX8 is transcriptionally regulated by KLF16 and promotes osteosarcoma progression.2025Journal of translational medicine
  7. SPICE1 promotes osteosarcoma growth by enhancing the deubiquitination of FASN mediated by USP10.2025Journal of translational medicine
  8. PSAT1 inhibits ferroptosis in osteosarcoma cells by activating the Xct/GPX4 signaling axis.2025Scientific reports
  9. Aurora-B: a novel biomarker in the invasion and metastasis of osteosarcoma.2024Biomarkers in medicine
  10. VCP enhances autophagy-related osteosarcoma progression by recruiting USP2 to inhibit ubiquitination and degradation of FASN.2024Cell death & disease
  11. USP3 promotes osteosarcoma progression via deubiquitinating EPHA2 and activating the PI3K/AKT signaling pathway.2024Cell death & disease
  12. Identification and experimental validation of Stearoyl-CoA desaturase is a new drug therapeutic target for osteosarcoma.2024European journal of pharmacology
  13. Pluripotent stem cell-derived CTLs targeting FGFR3-TACC3 fusion gene in osteosarcoma.2024International immunopharmacology
  14. Construction and validation of a novel NAD+ metabolism-related risk model for prognostic prediction in osteosarcoma.2024Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  15. Circ-CTNNB1 drives aerobic glycolysis and osteosarcoma progression via m6A modification through interacting with RBM15.2023Cell proliferation
  16. Role of let-7 family in the invasion and metastasis of osteosarcoma.2023Chinese medical journal
  17. The mechanism of VCP-mediated metastasis of osteosarcoma based on cell autophagy and the EMT pathway.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  18. Metabolism and senescence in the immune microenvironment of osteosarcoma: focus on new therapeutic strategies.2023Frontiers in endocrinology
  19. LRIG2 regulates cell proliferation, migration and apoptosis of osteosarcoma.2022BMC cancer
  20. Epithelial to Mesenchymal Transition Relevant Subtypes with Distinct Prognosis and Responses to Chemo- or Immunotherapies in Osteosarcoma.2022Journal of immunology research
  21. iTRAQ-based proteomic analysis of the molecular mechanisms and downstream effects of fatty acid synthase in osteosarcoma cells.2021Journal of clinical laboratory analysis
  22. LncRNA TUG1 promotes Ewing's sarcoma cell proliferation, migration, and invasion via the miR-199a-3p-MSI2 signaling pathway.2021Neoplasma
  23. A SEER-based nomogram accurately predicts prognosis in Ewing's sarcoma.2021Scientific reports
  24. The Role of Chemotherapy in the Survival Benefits of Patients Aged Older Than 40 Years With Osteosarcoma.2021Technology in cancer research & treatment
Earlier papers (2016–2020)19
  1. [Aurora kinase-B silencing promotes apoptosis of osteosarcoma 143B cells by ULK1 phosphorylation-induced autophagy].2020Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  2. MicroRNA‑487b‑3p inhibits osteosarcoma chemoresistance and metastasis by targeting ALDH1A3.2020Oncology reports
  3. SPAG5 promotes osteosarcoma metastasis via activation of FOXM1/MMP2 axis.2020The international journal of biochemistry & cell biology
  4. LHX2 promotes malignancy and inhibits autophagy via mTOR in osteosarcoma and is negatively regulated by miR-129-5p.2019Aging
  5. Anoikis resistant mediated by FASN promoted growth and metastasis of osteosarcoma.2019Cell death & disease
  6. CSN5 controls the growth of osteosarcoma via modulating the EGFR/PI3K/Akt axis.2019Experimental cell research
  7. Advanced development of ErbB family-targeted therapies in osteosarcoma treatment.2019Investigational new drugs
  8. Inhibitory effect of MSH6 gene silencing in combination with cisplatin on cell proliferation of human osteosarcoma cell line MG63.2019Journal of cellular physiology
  9. Parosteal osteosarcoma of the fibula in a middle-aged patient: A case report.2019Medicine
  10. Toosendanin induces the apoptosis of human Ewing's sarcoma cells via the mitochondrial apoptotic pathway.2019Molecular medicine reports
  11. SM‑164 enhances the antitumor activity of adriamycin in human U2‑OS cells via downregulation of X‑linked inhibitor of apoptosis protein.2019Molecular medicine reports
  12. Long noncoding RNA PCAT-1 acts as an oncogene in osteosarcoma by reducing p21 levels.2018Biochemical and biophysical research communications
  13. Lumbar spinal canal osteosarcoma: A case report.2018Medicine
  14. Effects of baicalein on proliferation, apoptosis, migration and invasion of Ewing's sarcoma cells.2017International journal of oncology
  15. Therapeutic effect of neoadjuvant chemotherapy combined with curettage to treat distal femoral osteosarcoma: A case report.2017Medicine
  16. Osteosarcoma in the coracoid process that mimicked an osteochondroma: A case report.2017Medicine
  17. ABT-737 potentiates cisplatin-induced apoptosis in human osteosarcoma cells via the mitochondrial apoptotic pathway.2017Oncology reports
  18. Overexpression of miR-140 Inhibits Proliferation of Osteosarcoma Cells via Suppression of Histone Deacetylase 4.2017Oncology research
  19. Let-7a suppresses macrophage infiltrations and malignant phenotype of Ewing sarcoma via STAT3/NF-κB positive regulatory circuit.2016Cancer letters

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 7 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 1.3%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 3320242025: 002025

4 hospitals in Nanchang for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)
Papers it led7
  1. Follow-up analysis and research of very low-risk and low-risk gastrointestinal stromal tumors after endoscopic resection.2024Scientific reports
  2. Comparable long‑term survival outcomes of endoscopic treatment versus surgical treatment for gastrointestinal stromal tumors with a diameter of 5-10 cm.2024Scientific reports
  3. Development and validation of a preoperative risk nomogram prediction model for gastric gastrointestinal stromal tumors.2024Surgical endoscopy
  4. Personalized Dose of Adjuvant Imatinib in Patients with Gastrointestinal Stromal Tumors: Results from a Population Pharmacokinetic Analysis.2023Drug design, development and therapy
  5. Gene polymorphisms affect postoperative imatinib plasma levels and edema in adults with gastrointestinal stromal tumor.2023Pharmacogenomics
  6. Hematologic toxicities of sunitinib in patients with gastrointestinal stromal tumors: a systematic review and meta-analysis.2022International journal of colorectal disease
  7. Enhancer of zeste homolog 2-mediated paired box 8 methylation promotes gastrointestinal stromal tumor progression through Wnt4 downregulation.2021Cancer gene therapy
Earlier papers (2016–2020)3
  1. The prognostic value of gender in gastric gastrointestinal stromal tumors: a propensity score matching analysis.2020Biology of sex differences
  2. Efficacy and safety of endoscopic submucosal dissection for large gastric stromal tumors.2020Clinics and research in hepatology and gastroenterology
  3. Endoscopic Resection of Gastric Submucosal Masses by a Dental Floss Traction Method.2019Canadian journal of gastroenterology & hepatology
All its trials on ClinicalTrials.gov, any status4
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05
  2. Second-line Pharmacotherapy Patterns and Outcomes of Advanced Gastrointestinal Stromal Tumor: A Real-world StudyStatus unknownNCT05440357Study siteStart 2022-07
  3. A Study of CS3007 in Subjects With Gastrointestinal Stromal TumorCompletedNCT04254939Study sitePhase 1/Phase 2Start 2019-08
  4. (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GISTCompletedNCT03465722Study sitePhase 3Start 2018-03

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 3 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 112025

4 hospitals in Nanchang for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgeryPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 2 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 1.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 0020242025: 002025

3 hospitals in Nanchang for Ewing sarcoma134 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 3 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.

Papers led
3
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
7
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 1120242025: 002025

2 hospitals in Nanchang for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 8

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2024-09
    Registry
    NCT06999031

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Nanchang UniversityNanchang

  2. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  3. Recruiting
    A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07518186

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Hangzhou, Nanchang, Nanjing, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an

  4. Recruiting
    A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
    Phase
    Phase 1
    Started
    2025-12
    Registry
    NCT07179679

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChengde, Chongqing, Guangzhou, Nanchang, Nanchong, Nanjing, Shanghai, Suzhou, Xi'an

  5. Recruiting
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2022-10
    Registry
    NCT05552222

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  6. Recruiting
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Registry
    NCT04973605

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chongqing, Fuzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou

  7. Recruiting
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    Phase
    Phase 3
    Started
    2021-10
    Registry
    NCT05020236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xuzhou, Zhengzhou

  8. Not yet recruiting
    A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)
    Phase
    Early phase 1
    Started
    2026-01
    Registry
    NCT07399444

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 4 listed hospitals as study sitesNanchang, Tianjin, Wuhan, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskDrug combinations
Departments in papersGastroenterology / hepatology
Papers it led3
  1. Identifying the prognostic significance of mitophagy-associated genes in multiple myeloma: a novel risk model construction.2024Clinical and experimental medicineFree full text
  2. A nomogram for predicting prognosis of multiple myeloma patients based on a ubiquitin-proteasome gene signature.2022AgingFree full text
  3. Obstructive jaundice caused by pancreatic plasmacytoma secondary to multiple myeloma: A case report and literature review.2021Journal of digestive diseases
Chinese-language papers (not in the count)2
  1. [Clinical characteristics and survival outcomes of patients with immunoglobulin A multiple myeloma in the bortezomib era: A single-center retrospective cohort study].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  2. [Application and Research Progress of Selinexor in Hematologic Tumors Other Than Multiple Myeloma --Review].2024Zhongguo shi yan xue ye xue za zhi
All its trials on ClinicalTrials.gov, any status18
  1. A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT06999031Lead sponsorEarly phase 1Start 2024-09
  2. Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple MyelomaStatus unknownNCT04194931Lead sponsorPhase 1Start 2019-12
  3. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07518186Study sitePhase 3Start 2026-05
  4. A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)Not yet recruitingNCT07399444Study siteEarly phase 1Start 2026-01
  5. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  6. A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell TumorsRecruitingNCT07179679Study sitePhase 1Start 2025-12
  7. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  8. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingNCT04973605Study sitePhase 1/Phase 2Start 2021-09
  9. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsRecruitingNCT05020236Study sitePhase 3Start 2021-10
  10. A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06934044Study sitePhase 1Start 2025-05
  11. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingNCT06208150Study sitePhase 3Start 2024-01
  12. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06158841Study sitePhase 3Start 2024-05
  13. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Active, not recruitingNCT06464991Study sitePhase 3Start 2024-03
  14. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05572515Study sitePhase 3Start 2023-03
  15. Study of 3D189 in Patients With Hematologic MalignanciesCompletedNCT05320809Study sitePhase 1Start 2022-08
  16. A Study of NINLARO® in Chinese Adults With Multiple MyelomaActive, not recruitingNCT05013190Study siteStart 2021-10
  17. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple MyelomaCompletedNCT03944057Study sitePhase 2Start 2019-09
  18. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.Active, not recruitingNCT03539744Study sitePhase 3Start 2018-10

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 1 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Nanchang for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
    Phase
    Phase 1
    Started
    2024-05
    Registry
    NCT06445803

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanchang, Shanghai

  2. Recruiting
    Study of YK012 in B-cell Acute Lymphoblastic Leukemia
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Registry
    NCT06580301

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesChangchun, Guangzhou, Guiyang, Hangzhou, Nanchang, Xuzhou

  3. Recruiting
    A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
    Phase
    Phase 1
    Started
    2024-09
    Registry
    NCT06927466

    Age 3 years to 25 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Nanchang, Shanghai, Suzhou, Wuhan, Xuzhou

  4. Recruiting
    A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Registry
    NCT05667506

    Age 3 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChongqing, Guangzhou, Hefei, Nanchang, Nanjing, Tianjin, Wuhan, Xuzhou

  5. Recruiting
    A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
    Phase
    Phase 2
    Started
    2022-01
    Registry
    NCT05334823

    Age 3 years to 21 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shenzhen, Suzhou, Tianjin, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesAntibody & targeted drugsMRD & relapseChildren

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 5 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 1.2%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 1120242025: 112025

1 hospital in Nanchang for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07208058

    Age 16 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesTreatment regimensDiagnosis & prognosisLymphoma & cancer-related HLH
Papers it led5
  1. Promising Targeted Therapies for Hemophagocytic Lymphohistiocytosis: A Translational Perspective Based on Immunopathology.2025Clinical reviews in allergy & immunology
  2. Refractory hemophagocytic lymphohistiocytosis secondary to polatuzumab vedotin plus rituximab and bendamustine.2024Annals of hematologyFree full text
  3. A novel prognosis-prediction model based on coagulation indicators in secondary hemophagocytic lymphohistiocytosis.2023Annals of hematologyFree full text
  4. Hemorrhagic fever with renal syndrome presenting as leukemoid reaction and hemophagocytic lymphohistiocytosis.2022Journal of medical virology
  5. Increased levels of serum interleukin-10 are associated with poor outcome in adult hemophagocytic lymphohistiocytosis patients.2021Orphanet journal of rare diseasesFree full text
Chinese-language papers (not in the count)2
  1. [Hemophagocytic lymphohistiocytosis following treatment with CAR-T therapy: two cases reports and literature review].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  2. [Research Advance of the Mechanisms, Clinical Characteristics and Treatment Strategy of Coagulation Dysfunction in Hemophagocytic Lymphohistiocytosis --Review].2022Zhongguo shi yan xue ye xue za zhi
All its trials on ClinicalTrials.gov, any status1
  1. A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])RecruitingNCT07208058Study sitePhase 3Start 2025-11
More papers found outside PubMed (not counted)3
  1. Efficacy and mechanism of BTK degrader nx-5948 in secondary hemophagocytic lymphohistiocytosis2025Bloodconference-abstract
  2. Efficacy and Safety of CD19-Specific CAR-T Cell Therapy Following Immunochemotherapy in Newly Diagnosed B-Cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis2023Bloodconference-abstract
  3. Hemophagocytic Lymphohistiocytosis Patients Need Intensive Care Can be Successfully Rescued By Timely Using Etoposide-Based HLH Regimens2022Bloodconference-abstract

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Nanchang for haemophilia A132 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with InhibitorCompletedNCT06289166Study sitePhase 2Start 2024-03
  2. Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without InhibitorCompletedNCT05619926Study sitePhase 2Start 2023-01

Run the PubMed searchClinicalTrials.gov

Blood disorders

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征

Led 1 of the 27 English-language PubMed papers on atypical haemolytic uraemic syndrome with an author in mainland China, 2021–2025: 3.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Nanchang for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome

No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Nanchang for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 4 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.8%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 112025

1 hospital in Nanchang for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

No open trial on neuromyelitis optica spectrum disorder lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImagingAntibodies & diagnosisBiologic drugs
Departments in papersRadiology / nuclear medicineNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 4 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.8%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 332025

2 hospitals in Nanchang for myasthenia gravis89 hospitals in China for myasthenia gravis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Myasthenia Gravis Registry in China
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT06241521

    Age not stated (registered criteria)

    Led by Huashan Hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Nanchang, Shanghai, Suzhou, Tianjin, Xi'an, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEye-only (ocular) myasthenia
Departments in papersNeurologyNeurosurgery

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 5 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 1.4%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 332025

2 hospitals in Nanchang for moyamoya disease47 hospitals in China for moyamoya disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07894107

    Age 12 years to 70 years (registered criteria)

    Led by Beijing Tiantan Hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanchang, Shanghai, Suzhou, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & blood flowStroke & bleeding outcomesRevascularisation surgery
Departments in papersRadiology / nuclear medicineNeurosurgeryNeurologyOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Nanchang for Takayasu arteritis100 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Takayasu Arteritis Clinical Trial in ChinaCompletedNCT02981979Study siteN/AStart 2016-12

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 4 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.4%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 222025

4 hospitals in Nanchang for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07121413

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesChengdu, Guangzhou, Hangzhou, Hohhot, Nanchang, Nanjing, Shanghai, Tianjin, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led4
  1. Identification and analysis of extracellular matrix and epithelial-mesenchymal transition-related genes in idiopathic pulmonary fibrosis by bioinformatics analysis and experimental validation.2025Gene
  2. Machine Learning-Driven Discovery of TRIM Genes as Diagnostic Biomarkers for Idiopathic Pulmonary Fibrosis.2025Medical science monitor : international medical journal of experimental and clinical research
  3. USP7 Promotes TGF-β1 Signaling by De-Ubiquitinating Smad2/Smad3 in Pulmonary Fibrosis.2024Discovery medicine
  4. microRNA-186 in extracellular vesicles from bone marrow mesenchymal stem cells alleviates idiopathic pulmonary fibrosis via interaction with SOX4 and DKK1.2021Stem cell research & therapy
Earlier papers (2016–2020)3
  1. Mesenchymal stem cell-derived extracellular vesicles suppress the fibroblast proliferation by downregulating FZD6 expression in fibroblasts via micrRNA-29b-3p in idiopathic pulmonary fibrosis.2020Journal of cellular physiology
  2. MicroRNA-448 overexpression inhibits fibroblast proliferation and collagen synthesis and promotes cell apoptosis via targeting ABCC3 through the JNK signaling pathway.2020Journal of cellular physiology
  3. Findings on cryptogenic organizing pneumonia: a case report and literature review.2020The Journal of international medical research
All its trials on ClinicalTrials.gov, any status4
  1. A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary FibrosisRecruitingNCT07121413Study sitePhase 2Start 2025-11
  2. Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary FibrosisTerminatedNCT06097260Study sitePhase 2Start 2023-11
  3. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04552899Study sitePhase 3Start 2021-03
  4. Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary FibrosisCompletedNCT01619085Study sitePhase 3Start 2012-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 4 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 002025

4 hospitals in Nanchang for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led4
  1. The therapeutic potential of Apigenin in amyotrophic lateral sclerosis through ALDH1A2/Nrf2/ARE signaling.2024Molecular medicine (Cambridge, Mass.)
  2. Parvalbumin interneurons dysfunction is potentially associated with FαMNs decrease and NRG1-ErbB4 signaling inhibition in spinal cord in amyotrophic lateral sclerosis.2023Aging
  3. Potential proteomic alteration in the brain of Tg(SOD1*G93A)1Gur mice: A new pathogenesis insight of amyotrophic lateral sclerosis.2022Cell biology international
  4. FUS Mutation Causes Disordered Lipid Metabolism in Skeletal Muscle Associated with ALS.2022Molecular neurobiology
Earlier papers (2016–2020)10
  1. FUS P525L mutation causing amyotrophic lateral sclerosis and movement disorders.2020Brain and behavior
  2. Preliminary Observation about Alteration of Proteins and Their Potential Functions in Spinal Cord of SOD1 G93A Transgenic Mice.2018International journal of biological sciences
  3. Aberrant Levels of Cystatin C in Amyotrophic Lateral Sclerosis: a Systematic Review and Meta Analysis.2018International journal of biological sciences
  4. Impaired tissue barriers as potential therapeutic targets for Parkinson's disease and amyotrophic lateral sclerosis.2018Metabolic brain disease
  5. Aldehyde Dehydrogenases 1A2 Expression and Distribution are Potentially Associated with Neuron Death in Spinal Cord of Tg(SOD1*G93A)1Gur Mice.2017International journal of biological sciences
  6. Polymorphism of rs3737597 in DISC1 Gene on Chromosome 1q42.2 in sALS Patients: a Chinese Han Population Case-Control Study.2017Molecular neurobiology
  7. Distributed Features of Vimentin-Containing Neural Precursor Cells in Olfactory Bulb of SOD1G93A Transgenic Mice: a Study about Resource of Endogenous Neural Stem Cells.2016International journal of biological sciences
  8. Changes in the Expression of FUS/TLS in Spinal Cords of SOD1 G93A Transgenic Mice and Correlation with Motor-Neuron Degeneration.2016International journal of biological sciences
  9. The Overexpression of TDP-43 Protein in the Neuron and Oligodendrocyte Cells Causes the Progressive Motor Neuron Degeneration in the SOD1 G93A Transgenic Mouse Model of Amyotrophic Lateral Sclerosis.2016International journal of biological sciences
  10. Potential role of gut microbiota and tissue barriers in Parkinson's disease and amyotrophic lateral sclerosis.2016The International journal of neuroscience

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led 1 of the 55 English-language PubMed papers on spinal muscular atrophy with an author in mainland China, 2021–2025: 1.8%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

2 hospitals in Nanchang for spinal muscular atrophy49 hospitals in China for spinal muscular atrophy

No open trial on spinal muscular atrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led1
  1. Benign monomelic amyotrophy of lower limb in a cohort of chinese patients.2021Brain and behavior
All its trials on ClinicalTrials.gov, any status1
  1. Adult Spinal Muscular Atrophy (SMA) China RegistryActive, not recruitingNCT05618379Study siteStart 2023-01

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

1 hospital in Nanchang for Behçet disease139 hospitals in China for Behçet disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
    Phase
    Phase 3
    Started
    2023-11
    Registry
    NCT06145893

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

4 hospitals in Nanchang for IgA nephropathy300 hospitals in China for IgA nephropathy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
    Phase
    Phase 3
    Started
    2025-07
    Registry
    NCT06963827

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBaotou, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Gaucher disease

戈谢病

Led no English-language PubMed papers on Gaucher disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Nanchang for Gaucher disease40 hospitals in China for Gaucher disease

No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 1 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Nanchang for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07282353

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Nanchang for primary sclerosing cholangitis89 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

南昌大学第一附属医院

First Affiliated Hospital of Nanchang University

南昌

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
First Affiliated Hospital of Nanchang Medical College; First Affiliated Hospital Of Nanchang University; First Affiliated Hospital of Nanchang Universty

Suggest a correctionDownload the data